CATALYST PHARMACEUTICALS INC (CPRX)
US14888U1016 - Common Stock
CPRX gets a fundamental rating of 8 out of 10. The analysis compared the fundamentals against 568 industry peers in the Biotechnology industry. CPRX has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. An interesting combination arises when we look at growth and value: CPRX is growing strongly while it also seems undervalued. This makes CPRX very considerable for value and growth and quality investing!
1. Profitability
1.1 Basic Checks
In the past year CPRX was profitable.
CPRX had a positive operating cash flow in the past year.
CPRX had positive earnings in each of the past 5 years.
Each year in the past 5 years CPRX had a positive operating cash flow.
1.2 Ratios
CPRX has a Return On Assets of 9.64%. This is amongst the best in the industry. CPRX outperforms 95.75% of its industry peers.
CPRX has a Return On Equity of 11.19%. This is amongst the best in the industry. CPRX outperforms 95.58% of its industry peers.
The Return On Invested Capital of CPRX (10.83%) is better than 96.11% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for CPRX is significantly above the industry average of 13.59%.
The 3 year average ROIC (20.38%) for CPRX is well above the current ROIC(10.83%). The reason for the recent decline needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.64% | ||
| ROE | 11.19% | ||
| ROIC | 10.83% |
ROA(3y)17.98%
ROA(5y)24.26%
ROE(3y)21.72%
ROE(5y)29.16%
ROIC(3y)20.38%
ROIC(5y)21.58%
1.3 Margins
CPRX has a better Profit Margin (15.68%) than 96.11% of its industry peers.
CPRX's Profit Margin has declined in the last couple of years.
The Operating Margin of CPRX (19.76%) is better than 96.46% of its industry peers.
In the last couple of years the Operating Margin of CPRX has declined.
With an excellent Gross Margin value of 86.67%, CPRX belongs to the best of the industry, outperforming 90.09% of the companies in the same industry.
CPRX's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 19.76% | ||
| PM (TTM) | 15.68% | ||
| GM | 86.67% |
OM growth 3Y-14.33%
OM growth 5YN/A
PM growth 3Y-34.21%
PM growth 5YN/A
GM growth 3Y0.51%
GM growth 5YN/A
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), CPRX is creating some value.
Compared to 1 year ago, CPRX has more shares outstanding
The number of shares outstanding for CPRX has been increased compared to 5 years ago.
There is no outstanding debt for CPRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
CPRX has an Altman-Z score of 17.75. This indicates that CPRX is financially healthy and has little risk of bankruptcy at the moment.
CPRX has a better Altman-Z score (17.75) than 91.50% of its industry peers.
CPRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 17.75 |
ROIC/WACC0.91
WACC11.91%
2.3 Liquidity
CPRX has a Current Ratio of 5.14. This indicates that CPRX is financially healthy and has no problem in meeting its short term obligations.
CPRX's Current ratio of 5.14 is in line compared to the rest of the industry. CPRX outperforms 55.40% of its industry peers.
CPRX has a Quick Ratio of 4.94. This indicates that CPRX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 4.94, CPRX is in line with its industry, outperforming 55.58% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.14 | ||
| Quick Ratio | 4.94 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 63.89% over the past year.
CPRX shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 25.48% yearly.
CPRX shows a strong growth in Revenue. In the last year, the Revenue has grown by 85.90%.
Measured over the past years, CPRX shows a very strong growth in Revenue. The Revenue has been growing by 280.39% on average per year.
EPS 1Y (TTM)63.89%
EPS 3Y25.48%
EPS 5YN/A
EPS Q2Q%220.69%
Revenue 1Y (TTM)85.9%
Revenue growth 3Y49.53%
Revenue growth 5Y280.39%
Sales Q2Q%25.33%
3.2 Future
CPRX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 32.43% yearly.
CPRX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 14.81% yearly.
EPS Next Y53.42%
EPS Next 2Y41.43%
EPS Next 3Y34.8%
EPS Next 5Y32.43%
Revenue Next Year23.01%
Revenue Next 2Y20.62%
Revenue Next 3Y18.39%
Revenue Next 5Y14.81%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 18.03, the valuation of CPRX can be described as rather expensive.
Based on the Price/Earnings ratio, CPRX is valued cheaper than 95.93% of the companies in the same industry.
When comparing the Price/Earnings ratio of CPRX to the average of the S&P500 Index (27.73), we can say CPRX is valued slightly cheaper.
The Price/Forward Earnings ratio is 13.13, which indicates a correct valuation of CPRX.
Based on the Price/Forward Earnings ratio, CPRX is valued cheaply inside the industry as 96.81% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.83, CPRX is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.03 | ||
| Fwd PE | 13.13 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, CPRX is valued cheaply inside the industry as 95.93% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, CPRX is valued cheaper than 97.70% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 12.91 | ||
| EV/EBITDA | 17.84 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The excellent profitability rating of CPRX may justify a higher PE ratio.
A more expensive valuation may be justified as CPRX's earnings are expected to grow with 34.80% in the coming years.
PEG (NY)0.34
PEG (5Y)N/A
EPS Next 2Y41.43%
EPS Next 3Y34.8%
5. Dividend
5.1 Amount
CPRX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CATALYST PHARMACEUTICALS INC
NASDAQ:CPRX (12/20/2024, 8:03:48 PM)
After market: 21.27 0 (0%)21.27
-0.19 (-0.89%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners79.54%
Inst Owner Change-2.36%
Ins Owners7.52%
Ins Owner Change-0.86%
Market Cap2.54B
Analysts87.14
Price Target32.9 (54.68%)
Short Float %5.44%
Short Ratio6.58
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)17.38%
Min EPS beat(2)12.21%
Max EPS beat(2)22.55%
EPS beat(4)4
Avg EPS beat(4)12.42%
Min EPS beat(4)0.24%
Max EPS beat(4)22.55%
EPS beat(8)7
Avg EPS beat(8)9.97%
EPS beat(12)8
Avg EPS beat(12)4.33%
EPS beat(16)11
Avg EPS beat(16)4.38%
Revenue beat(2)1
Avg Revenue beat(2)2.98%
Min Revenue beat(2)-1.58%
Max Revenue beat(2)7.55%
Revenue beat(4)3
Avg Revenue beat(4)2.15%
Min Revenue beat(4)-1.58%
Max Revenue beat(4)7.55%
Revenue beat(8)7
Avg Revenue beat(8)3.1%
Revenue beat(12)9
Avg Revenue beat(12)2.48%
Revenue beat(16)11
Avg Revenue beat(16)1.66%
PT rev (1m)6.49%
PT rev (3m)6.99%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)5.03%
EPS NY rev (3m)10.96%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.03%
Revenue NY rev (1m)1.63%
Revenue NY rev (3m)2.19%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.03 | ||
| Fwd PE | 13.13 | ||
| P/S | 5.84 | ||
| P/FCF | 12.91 | ||
| P/OCF | 12.89 | ||
| P/B | 4.17 | ||
| P/tB | 5.85 | ||
| EV/EBITDA | 17.84 |
EPS(TTM)1.18
EY5.55%
EPS(NY)1.62
Fwd EY7.62%
FCF(TTM)1.65
FCFY7.75%
OCF(TTM)1.65
OCFY7.76%
SpS3.64
BVpS5.1
TBVpS3.63
PEG (NY)0.34
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.64% | ||
| ROE | 11.19% | ||
| ROCE | 13.98% | ||
| ROIC | 10.83% | ||
| ROICexc | 27.91% | ||
| ROICexgc | 105.6% | ||
| OM | 19.76% | ||
| PM (TTM) | 15.68% | ||
| GM | 86.67% | ||
| FCFM | 45.23% |
ROA(3y)17.98%
ROA(5y)24.26%
ROE(3y)21.72%
ROE(5y)29.16%
ROIC(3y)20.38%
ROIC(5y)21.58%
ROICexc(3y)212.24%
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)26.3%
ROCE(5y)27.86%
ROICexcg growth 3Y-0.3%
ROICexcg growth 5YN/A
ROICexc growth 3Y-37.77%
ROICexc growth 5YN/A
OM growth 3Y-14.33%
OM growth 5YN/A
PM growth 3Y-34.21%
PM growth 5YN/A
GM growth 3Y0.51%
GM growth 5YN/A
F-Score6
Asset Turnover0.62
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 0.93% | ||
| Cap/Sales | 0.08% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 160.82% | ||
| Profit Quality | 288.52% | ||
| Current Ratio | 5.14 | ||
| Quick Ratio | 4.94 | ||
| Altman-Z | 17.75 |
F-Score6
WACC11.91%
ROIC/WACC0.91
Cap/Depr(3y)166.9%
Cap/Depr(5y)100.14%
Cap/Sales(3y)0.26%
Cap/Sales(5y)0.15%
Profit Quality(3y)163.58%
Profit Quality(5y)131.84%
High Growth Momentum
Growth
EPS 1Y (TTM)63.89%
EPS 3Y25.48%
EPS 5YN/A
EPS Q2Q%220.69%
EPS Next Y53.42%
EPS Next 2Y41.43%
EPS Next 3Y34.8%
EPS Next 5Y32.43%
Revenue 1Y (TTM)85.9%
Revenue growth 3Y49.53%
Revenue growth 5Y280.39%
Sales Q2Q%25.33%
Revenue Next Year23.01%
Revenue Next 2Y20.62%
Revenue Next 3Y18.39%
Revenue Next 5Y14.81%
EBIT growth 1Y-37.87%
EBIT growth 3Y28.1%
EBIT growth 5YN/A
EBIT Next Year152.44%
EBIT Next 3Y28.8%
EBIT Next 5YN/A
FCF growth 1Y160.29%
FCF growth 3Y47.15%
FCF growth 5YN/A
OCF growth 1Y160.4%
OCF growth 3Y47.22%
OCF growth 5YN/A